MBOT — Stock Film
STOCK FILMSCENE 1/10MBOT · $1.45
Stock Expert AI presents
MBOT
Microbot Medical Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Microbot Medical Inc. What it actually does.

Develops robotic endoluminal surgery devices. Focuses on minimally invasive surgical solutions. Now — the numbers.

on the stock market since 1992
43 employees
$66.1M market value
Revenue last year:
$0
The loss that same year:
$13.1M
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$78.6M
DEBT: $865K
At this pace, that money lasts about 6 years.

At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
3 / 8
EXPECTATIONS MET OR BEATEN
3
Nov 2024
Aug 2026
3 TIMES IN THE LAST 8 QUARTERS
It misses the bar more often than not.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
15
very weak

Clearly below the class average.

FINANCIAL STRENGTH
82
very strong

Debt is low and cash is strong; the finances stand solid.

VALUATION
41
weak

Clearly below the class average.

GROWTH
35
weak

Clearly below the class average.

PRICE MOMENTUM
20
very weak

Clearly below the class average.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 84% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $78.6M in the vault; even if every debt were paid off, $77.7M would remain.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 20 buys and 0 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $13.1M against $0 in annual sales.

2
THE RISKS · 2/3
The business trails its class

Measured against its sector, the quality of the business sits below the class average. Report-card grade: 15/100.

3
THE RISKS · 3/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 20/100. For a turnaround signal, the stock first needs to close the gap with the market.

FINALE · THE GRADE
F
28 / 100 · MoonshotScore

On our five-subject report card, MBOT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: MBOT is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (41/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film